| AGEP | Acute Generalized Exanthematous Pustulosis |
| BRAFi | BRAF-inhibitors |
| BSA | Body Surface Area |
| CTLA-4 | T lymphocyte-associated antigen-4 |
| DRESS | Drug Reaction with Eosinophilia and Systemic Symptoms |
| EGFR | Epidermal Growth Factor Receptor Inhibitors |
| ICIs | Immune Checkpoint-Inhibitors |
| IGF-1 | Insulin-like Growing Factor-1 |
| irAE | Immune-related Adverse Event |
| MAPK | Mitogen-activated Protein Kinase |
| MEKi | MEK-inhibitors |
| NMSC | Nonmelanoma Skin Cancer |
| PD-1 | Programmed Cell Death Protein 1 |
| PD-L1 | Programmed Death Ligand 1 |
| PTCH1 | Patched Homologue 1 |
| SCC | Squamous Cell Carcinomas |
| SMO | Smoothened Homologue |